Cognitive & Nootropic / Level D / Early Research / Last reviewed 2026-08-27

NA-Semax-Amidate Evidence Guide

Evidence for NA-Semax-Amidate is too preliminary to support a research protocol with confidence. Like N-Acetyl Selank, this is a modified derivative of a Russian peptide with no independent clinical trials. The parent Semax has only Russian-sourced data. Cerebrolysin is a far better-evidenced starting point for cognitive enhancement research.

Our Take

Evidence context: Modified ACTH-analog cognitive peptide research (no independent clinical data)
Evidence grade: Level D
Confidence: Low
Reference context: Reported research reference: No established human protocol with independent validation

Benefits and Evidence

Cognitive Enhancement (extrapolated from Semax): Level D, mostly non-human evidence - Based on Semax research demonstrating improved attention, memory formation, and learning in both animal models and human studies. Direct evidence for the doubly modified form is limited.
Enhanced Metabolic Stability: Level D, mostly non-human evidence - Dual terminal modification (acetylation + amidation) is a well-established peptide engineering approach that substantially reduces susceptibility to aminopeptidases and carboxypeptidases.
Neuroprotection (extrapolated): Level D, mostly non-human evidence - No direct clinical trials on NA-Semax-Amidate exist. Neuroprotective claims are extrapolated from parent compound Semax: Gusev & Skvortsova (2003, Brain Res Bull) demonstrated Semax efficacy in ischemic stroke. The N-acetyl and C-amide modifications increase serum half-life ~20-fold, theoretically improving CNS bioavailability.

Side Effects and Warnings

Headache (extrapolated from Semax)
Mild nasal irritation (intranasal)
Dizziness (rare)
Irritability at high doses
No direct human clinical trials exist for NA-Semax-Amidate
Safety and efficacy data extrapolated from Semax research
Dual modification may create unpredictable pharmacological differences
Not approved for medical use in any jurisdiction

Research Dosage References

<strong>Intranasal</strong> - 100-600 mcg - Once or twice daily - Dosing extrapolated from Semax protocols. Enhanced stability may allow lower doses than standard Semax.
<strong>Subcutaneous</strong> - 200-400 mcg - Once daily - Subcutaneous route provides consistent absorption. Experimental use only.

Mechanism of Action

NA-Semax-Amidate is expected to act through Semax's established mechanisms with enhanced duration: (1) Upregulation of BDNF and its receptor TrkB in hippocampal and cortical neurons; (2) Modulation of dopaminergic and serotonergic neurotransmission in the prefrontal cortex; (3) Activation of the melanocortin system via MC4R receptors; (4) Enhancement of NGF and GDNF expression; (5) Anti-inflammatory effects through suppression of IL-1beta and TNF-alpha in activated microglia. The dual terminal modifications improve metabolic resistance, potentially allowing lower effective doses and less frequent administration.

Legal Status

Unregulated research peptide in most countries.

Primary Sources

Semax, an analog of ACTH 4-10, regulates expression of immune response genes. Molecular Genetics and Genomics, 2010.
Semax (ACTH 4-10 analogue) modulates BDNF and its receptor in the rat hippocampus. Neuroscience Letters, 2006.
Peptide design strategies for improved bioavailability and metabolic stability. Amino Acids, 2006.

Quick Answers

Where is the strongest evidence for NA-Semax-Amidate?

What are the main side effects of NA-Semax-Amidate?

NA-Semax-Amidate side effects and warning signals include Headache (extrapolated from Semax), Mild nasal irritation (intranasal), Dizziness (rare), Irritability at high doses, and No direct human clinical trials exist for NA-Semax-Amidate.

What evidence level is NA-Semax-Amidate?

NA-Semax-Amidate is rated Level D; the listed research status is Early Research.